GlassScriptPhysician profile
Andrew J Robitaille
NPI 1316414162
$1,592.65
in general payments reported to CMS, 2019-2025
14 companies · $713 in 2025
The $713 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $418 · 2023: $23.26 · 2024: $29.13 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $405.75 | 2021-2023 | Blueprint Patient Specific Instrumentation |
| Lundbeck LLC | $312.62 | 2025 | Vyepti |
| Abbvie INC. | $241.98 | 2025 | |
| Treace Medical Concepts, INC. | $237.84 | 2021-2022 | |
| Lima USA, INC. | $105.38 | 2022 | |
| Ethicon US, LLC | $51.28 | 2022 | |
| Depuy Synthes Sales INC. | $50.08 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.83 | 2025 | Relistor, Trulance |
| Teva Pharmaceuticals USA, INC. | $36.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $36.32 | 2025 | Spravato |
| Valinor Pharma, LLC | $20.83 | 2025 | Movantik |
| Pfizer INC. | $19.74 | 2025 | |
| Gilead Sciences, INC. | $18.79 | 2025 | |
| Collegium Pharmaceutical, INC. | $13.62 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Robitaille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.